Jeffrey W. Albers appointed President of Algeta US
Algeta ASA announced the appointment of Jeffrey W. Albers as President of Algeta US, the Company’s new US commercial operation. He takes up his position immediately and will join Algeta’s executive management team, reporting to President and CEO, Andrew Kay.
Mr. Albers will work closely with Algeta’s senior management as part of the executive management team to enable Algeta’s US commercial operations; the current plans for which include the phased building of a sales force and a marketing and medical affairs team ahead of the launch of Alpharadin (radium-223 chloride) for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases, pending approval.
Mr. Albers joins Algeta from Genzyme (Sanofi), where he spent the past seven years in senior commercial and corporate development positions, most recently as Vice President, US Hematology & Oncology Business. In this role, Mr. Albers had P&L responsibility for a USD 250m business that included multiple marketed products along with a pipeline of products to treat hematologic and solid tumor malignancies. He built and led a 135-person team spanning sales, operations, marketing, managed care, pricing and reimbursement, training and medical affairs. He was also involved in evaluating in-licensing opportunities. Mr. Albers played a key role in the successful US launch of Mozobil® and integrating Campath® and Leukine® into the portfolio (acquired from Bayer in 2009) involving a significant field force restructuring. After the acquisition of Genzyme by Sanofi he represented Genzyme on the US Oncology Integration Team. Prior to Genzyme, he spent five years (2000-2005) as an attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo, where he focused on life sciences transactional work. He has prior experience as a sales representative for Pfizer, Inc. Mr. Albers has a B.Sc. in Marketing from Indiana University, and a law degree (J.D.) and MBA from Georgetown University (Washington, DC).
Other news from the department people
